23andMe's previous independent directors announced their resignation in a letter to Wojcicki in September, writing that they disagreed with her about the "strategic direction for the company."

The genetic-testing company, once valued at $6 billion, has struggled since it went public in 2021 through a special purpose acquisition company, or SPAC. Shares were hovering below $1 until 23andMe announced a 1-for-20 reverse stock split of the Company's Class A and Class B common stock earlier this month.